From Personal Challenge to Public Good: How Endurance Athletes Are Transforming Rare Disease Research

Endurance athletes are defined by their ability to push through physical and mental barriers, often training for months or years to complete a single event like an Ironman triathlon, a 100‑mile ultramarathon, or a multi‑day cycling race. Yet an increasing number of these athletes are channeling their grit into a second, equally demanding mission: funding research for rare and neglected diseases. Where traditional philanthropy often relies on wealthy donors or large foundations, these athletes leverage their own bodies—and the communities that rally around them—to generate millions of dollars for conditions that pharmaceutical companies and government agencies routinely overlook. This grassroots model of medical funding is not only accelerating drug development but also reshaping how the public engages with science.

The scale of the problem is staggering. Of the more than 7,000 known rare diseases, only about 5% have any approved treatment. Neglected tropical diseases, which primarily affect low‑income populations, receive a fraction of the global health budget relative to their burden. Endurance athletes, by committing to grueling physical undertakings and asking their networks to support a cause, are filling a critical gap. Their efforts have funded everything from basic genetic studies to late‑stage clinical trials, and the results are beginning to show tangible progress for patients who have waited decades for hope.

Why Endurance Athletes Choose Rare and Neglected Diseases

The connection between endurance sports and rare disease advocacy is not accidental. Both realms require extraordinary perseverance, a long‑term horizon, and the willingness to endure discomfort without immediate reward. Many athletes are drawn to rare disease causes because they see a direct parallel: just as a marathoner trains for months for a single day, a family caring for a child with a rare genetic disorder fights an uphill battle every day with no guarantee of a cure. This empathy, combined with the athlete’s platform, creates a powerful engine for change.

Personal Stories That Ignite Fundraising

Perhaps the most compelling drivers are personal connections. When an athlete’s own child, sibling, or friend is diagnosed with a rare disease, the motivation shifts from abstract altruism to a fight for survival. Take the case of professional triathlete Amy Marsh. After her daughter was diagnosed with CDKL5 deficiency disorder—a rare genetic condition causing severe epilepsy and developmental delay—Marsh launched the Race for Research initiative. She began using every race as a platform, from Ironman events to local 5Ks, raising funds directly for the CDKL5 Research Foundation. Within three years, her efforts helped bankroll a preclinical trial for a gene therapy that is now moving toward human testing.

Similarly, ultrarunner Travis Macy—author of The Ultra Mindset—dedicated a 100‑mile run to raise awareness for Leber’s hereditary optic neuropathy (LHON), the condition that caused his brother to lose his vision. Macy’s campaign, Race for Sight, combined a documentary film, live race updates, and a direct‑donation portal to bring in over $250,000. That money funded a natural history study that ultimately helped researchers identify a drug candidate now in Phase II trials.

These personal stories generate viral interest. When an athlete posts a training update that includes a plea for donations to a disease that most people have never heard of, the emotional weight cuts through the noise. Friends, followers, and even strangers are more likely to click a link that leads to a child’s face or a brother’s story than a generic research charity.

The Charity Bib Model and Mass Participation

Beyond individual athletes, mass‑participation events have formalized the link between endurance sports and rare disease funding. The Ironman Foundation, for example, offers “charity slots” to entrants who commit to raising at least $1,500 for a partner nonprofit. Many of these nonprofits focus on specific rare diseases. In 2023, Team Impact—a group of endurance athletes who race for rare disease research—raised over $2.7 million through this model. The money flowed to causes such as Dravet syndrome, cystinosis, and Huntington’s disease.

The beauty of the charity bib approach is that it scales. A single marathon can host hundreds of charity runners, each tapping their own social networks. The Boston Marathon’s Official Charity Program includes organizations like the Rare Disease Research Foundation, and in 2024, those runners collectively raised over $8 million. For the athletes, the fundraising commitment adds a layer of accountability: they are not just running for a personal best but for the families who are counting on them.

How the Raised Money Translates into Research

For researchers, athlete‑raised funds are often more flexible than government grants or pharmaceutical partnerships. National Institutes of Health (NIH) grants, for instance, can take years to secure and come with strict parameters that may not align with innovative but unproven approaches. Private philanthropy—especially from grassroots movements—can be deployed rapidly to de‑risk early‑stage studies, fund pilot trials, or cover the “valley of death” between basic discovery and clinical application.

Funding Preclinical Work and Biomarker Discovery

Many rare disease research efforts begin in small academic labs where scientists are chasing the underlying biology. Athlete‑funded grants have helped pay for expensive reagents, animal models, and genetic sequencing that would otherwise sit on the “underfunded” list. A notable example is the Rare Genomics Institute, which partners with endurance events to offer grants for whole‑exome sequencing of undiagnosed patients. In one case, fundraising from a team of five cyclists riding across Colorado led to the identification of a novel SYNGAP1 mutation in a young girl. That finding opened a new line of research into synaptic function and intellectual disability.

Biomarker discovery is another area where athlete dollars punch above their weight. The MitoAction foundation, which supports patients with mitochondrial disease, has used funds from triathlon‑based challenges to bankroll a multi‑center study on blood‑based biomarkers. These biomarkers allow researchers to rapidly screen potential drugs without waiting years for clinical outcomes, dramatically accelerating the trial pipeline.

Clinical Trials: From Parents to Phase II

Perhaps the most visible success of athlete‑driven funding is its role in getting trials off the ground. The Cure SMA organization—though focused on spinal muscular atrophy, not strictly rare but still classified—famous for its ice bucket challenge precursor, actually began with small‑scale running events. Today, endurance athletes continue that tradition. The Team Maddie project, named after a girl with Sanfilippo syndrome (a devastating neurodegenerative disease), runs an annual 100‑mile ultra relay that has generated over $1.2 million since 2019. That money directly funded a Phase II trial of a gene therapy that has already shown stabilization in some children.

Similarly, the Niemann‑Pick Disease Type C (NPC) Research Foundation has leveraged “run for a cure” races to fund a pivotal trial of arimoclomol, a drug that metabolically targets cholesterol trafficking. With a patient population of fewer than 500 in the U.S., traditional drug development economics are impossible. But $850,000 from four years of endurance fundraising made the difference, and the drug is now under FDA review.

Notable Initiatives and Their Measurable Impact

The landscape is rich with examples of endurance athletes moving the needle. Here are a few standout programs that demonstrate the model at scale.

Team Liquid’s “Run for Life”

Not all endurance athletes are professional runners. In 2021, the esports organization Team Liquid partnered with its gaming community to launch Run for Life, a virtual event where participants could log miles in any sport. The cause: cystic fibrosis (CF), a rare genetic disease affecting the lungs and digestive system. By combining the endurance challenge with a live‑streamed marathon, Team Liquid raised over $400,000 in its first year. The funds went to the Cystic Fibrosis Foundation and were earmarked for a Phase II trial of a triple‑combination therapy tailored to rare CF mutations. The campaign grew in 2023 to raise $1.1 million, with participants from 64 countries logging a cumulative 2.3 million miles.

The “Race Against Dysautonomia”

Dysautonomia—a group of disorders affecting the autonomic nervous system—includes conditions like POTS (postural orthostatic tachycardia syndrome), which has gained significant attention since the COVID‑19 pandemic. Yet research funding remains sparse. The Dysautonomia International organization created the Race Against Dysautonomia series, which includes 5Ks, half‑marathons, and triathlons. In 2024, a group of ten endurance athletes from the “POTS Warriors” team raised over $300,000 through a combination of personal fundraising, corporate matching, and a 24‑hour ultramarathon event. That money funded the first multicenter study of intravenous immunoglobulin (IVIG) for autoimmune‑mediated POTS, a trial that has enrolled 120 patients and expects results in 2026.

Ultramarathons for Neglected Tropical Diseases

Rare diseases aren’t the only focus. Neglected tropical diseases (NTDs) like leishmaniasis, Chagas disease, and schistosomiasis affect hundreds of millions but receive minimal R&D funding. The Worldwide Hospice Foundation (not directly, but similar) and the Drugs for Neglected Diseases initiative (DNDi) have both benefited from endurance events. In 2023, British ultrarunner Sophie Radcliffe ran 250 miles across the Sahara to raise funds for NTD research. Her campaign, Sand & Science, netted $180,000, which DNDi used to complete a Phase I trial of a new oral treatment for visceral leishmaniasis in East Africa.

The Technology and Community Behind Modern Fundraising

Endurance athletes in 2025 have tools their predecessors could only dream of. Social media platforms allow real‑time tracking of both the athlete’s progress and the fundraising thermometer. Platforms like GiveLively and Classy enable peer‑to‑peer campaigns that automatically update donors. Live‑streaming apps such as Twitch and YouTube have allowed endurance challenges to become participatory spectacles: a viewer can donate and, in return, vote on which training route the athlete takes or even which disease research project gets a bonus lump sum.

Virtual races—where participants join from any location and run on treadmills or local trails—have exploded since the pandemic. The Rare Disease Day Virtual Marathon in 2024 drew 12,000 registrants from 87 countries, raising $1.4 million. The event used a simple model: a registration fee plus optional donations, with 100% of proceeds going to the Rare Disease Research Foundation. For the cost of a single entry, a runner in Tokyo could support a gene therapy trial for Angelman syndrome happening in Boston.

Challenges and Criticisms of the Athlete‑Funding Model

While the trend is overwhelmingly positive, it is not without challenges. One concern is the “charity mandate” that can pressure athletes to prioritize fundraising over performance or safety. Some athletes have reported burnout from juggling intense training schedules with constant donation requests. Additionally, the model can inadvertently favor diseases with the most photogenic or sympathetic stories, leaving less visible conditions—like certain ultra‑rare metabolic disorders—at a disadvantage.

There is also the issue of overhead. Many small rare disease foundations lack the infrastructure to manage high volumes of small donations efficiently. Some have turned to dedicated fiscal sponsors like the Rare Disease Action Network, but this adds administrative overhead that can eat into research funds. Transparency remains crucial: donors need to know that their $50 isn’t going to race‑t‑shirts or event logistics.

Finally, there is a risk that athlete‑driven funding becomes a stopgap rather than a catalyst. If governments and pharmaceutical companies offload their responsibility for rare disease research onto the backs of individual athletes, the system becomes unsustainable long‑term. Advocates argue that endurance fundraising should be a supplement to, not a substitute for, public investment and corporate responsibility.

The Future: Scaling Impact Through Community and Science

Despite these challenges, the future of athlete‑driven funding looks bright. Innovations in data sharing, such as the Rare Disease Research Cloud, allow donors to track exactly how their money is used from lab bench to patient bedside. Athletes can now offer donors a transparent view of milestones: “Your funds have completed the enzyme assay phase; next up is mouse model creation.” This accountability builds trust and encourages repeat giving.

Corporate partnerships are also deepening. Running shoe brands like Hoka and Brooks have created signature charity shoes where a portion of each sale goes to a rare disease research fund. Energy‑gel companies like Gu Energy Labs sponsor athlete teams that commit specific donation percentages. In 2024, the Endurance for Rare Disease coalition launched, bringing together 15 professional athletes, 20 research institutions, and 30 patient advocacy groups to coordinate annual fundraising roadmaps. Their goal: raise $50 million by 2030 for a basket of 50 rare diseases.

Moreover, the growing field of participatory science is bringing athletes into the research process itself. Some studies are now embedding wearable sensors on athletes during multi‑day events to collect data on metabolism, immune function, and muscle repair—and then comparing that data to disease states. For example, the Mitochondria in Motion study asks athletes to donate blood and muscle biopsies before and after races to study how mitochondrial function adapts to extreme stress. The insights gained help researchers understand mitochondrial diseases like Leigh syndrome and MELAS. Athletes become both funders and subjects, accelerating the cycle of discovery.

How You Can Get Involved

The barrier to entry for athlete‑driven fundraising is lower than ever. You do not need to run an ultramarathon or swim across a channel to make a difference. Many online platforms allow you to create a personal fundraising page tied to a race you already planned to enter—or even a virtual challenge you create yourself. Dreaming for Others (a program founded by a rare disease mom) connects athletes with specific research projects needing funding. You can choose a disease, set a mileage goal, and start raising money within minutes.

For those who prefer to donate rather than run, supporting these athlete‑fundraisers directly is equally powerful. A single donation of $25 might cover the cost of a reagent for a single experiment, while $5,000 can fund a half‑time lab technician’s salary for a month. Every dollar counts in the world of rare disease research, where even small studies can yield breakthrough insights.

As endurance athletes continue to push their own limits, they are simultaneously pushing the boundaries of what is possible in medical science. The partnership between sweat and science is producing a new kind of hope—one that is earned mile by mile, step by step, and donation by donation. For the millions waiting for treatments, that hope is the greatest reward of all.